A judge has questioned AMP Financial Planning over whether it breached court orders to compensate customers after finding the firm failed to prevent a now banned adviser from churning life insurance for higher commissions.
US-based mozzarella giant Leprino Foods has succeeded in removing Canadian dairy company Saputo’s ‘Ascend’ trade mark for non-use.
A judge has savaged Shine Lawyers over its failure to present a signed settlement agreement to the court a month after Johnson & Johnson Medical and unit Ethicon agreed to pay $300 million to settle two pelvic mesh class actions, ordering the firm to explain on the record what steps have been taken to finalise the settlement.
US-based multinational firm Jones Day has lured a partner from Clayton Utz to join its intellectual property team in Melbourne.
The Australian Securities and Investments Commission has suffered a defeat in proceedings alleging the Commonwealth Bank of Australia accepted conflicted remuneration through the sale of its Essential Super product, with a judge finding the regulator “ignored the circumstances” in which the product was distributed.
Two former executives of defunct electronics retailer Dick Smith have asked the High Court to hear their challenge to a $11.8 million damages award for approving a dividend payment the company could not afford.
The lead applicant in a class action against Bayer over its Essure contraceptive device has admonished the drug makerâs request for her medical records since the age of 14, saying it had âno basisâ and was a âfishing exerciseâ.
A judge has signed off on a $7.2 million penalty against Dixon Advisory after the company admitted to ASIC allegations that its advisors failed to act in its clients’ best interests by recommending they invest in a risky US-based real estate investment fund.
The sacked CEO of Orix Australia has abandoned his challenge to a ruling allowing a set-off defence for the fleet management company in his case for unpaid leave entitlements and penalties.
German biotech Fresenius Kabi has struck back at Samsung Bioepis’s latest attack on the validity of its patents for a liquid formulation of top selling immunosuppressant drug Humira, accusing the Korean company of causing its sales to flag by infringing the patent.